Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2020.203 | The safety of high flow nasal cannula and noninvasive ventilation for treatment of patients with COVID-19 complicated by respiratory failure |
Prof. HUI David Shu Cheong 許樹昌教授 |
| 2019.451 | A 24-week multi-center, double-blind, placebo controlled dose-range finding study to investigate the efficacy and safety of oral QBW251 in COPD patients on triple inhaled therapy (LABA/LAMA/ICS) |
Prof. HUI David Shu Cheong 許樹昌 |
| 2020.220 | Tropism and pathogenesis of SARS-CoV-2 in human macrophages |
Prof. HUI David Shu Cheong 許樹昌 |
| 2018.250 | Observational study to assess frailty of subjects during ZOSTER-006 and ZOSTER-022 and HZ efficacy, immunogenicity and safety of HZ/su by frailty status. | Prof. HUI David Shu Cheong |
| 2020.229 | Long-term longitudinal comparisons of health and immunity status in convalescent COVID-19 and vaccinated cohorts in Hong Kong |
Prof. HUI David Shu Cheong 許樹昌 |
| 2019.392 | A phase III, randomized, observer-blind, placebo controlled, multicenter clinical trial to assess Herpes Zoster recurrence and the reactogenicity, safety and immunogenicity of GSK Biologicals’ Herpes Zoster vaccine (HZ/su) when administered intramuscularly on a 0 and 2 month schedule to adults ≥ 50 years of age with a prior episode of Herpes Zoster. |
Prof. HUI David Shu Cheong 許樹昌 |
| 2020.089 | A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Moderate COVID-19 Compared to Standard of Care Treatment |
Dr. HUI David Shu Cheong 許樹昌 |
| 2020.088 | A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Severe COVID-19 |
Dr. HUI David Shu Cheong 許樹昌 |
| 2018.613 | A randomized, double blind, placebo controlled trial of intravenous N-acetylcysteine and oseltamivir versus intravenous 5% dextrose and oseltamivir alone in adults hospitalized with influenza complicated by lower respiratory tract infection |
Prof. HUI David Shu Cheong 許樹昌 |
| 2019.510 | PREPARE Study: PRevalence of the Eosinophilic Phenotype Among SeveRE Asthma Patients in AstraZeneca International Region. A Multinational, Cross-Sectional, Multicenter Study |
Prof. HUI David Shu Cheong 許樹昌教授 |
| 2018.433 | A PHASE III, RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BALOXAVIR MARBOXIL IN COMBINATION WITH STANDARD-OF-CARE NEURAMINIDASE INHIBITOR IN HOSPITALIZED PATIENTS WITH SEVERE INFLUENZA |
Prof. HUI David Shu Cheong 許樹昌 |
| 2016.191 | A phase IIIb, open-label, multi-country, multi-centre, long-term follow-up study (ZOE-LTFU) of studies 110390 and 113077 (ZOSTER-006/022) to assess the prophylactic efficacy, safety, and immunogenicity persistence of GSK Biologicals’ Herpes Zoster subunit (HZ/su) vaccine and assessment of 1 or 2 additional doses on a 0 or 0, 2-month schedule in two subgroups of older adults. |
Prof. HUI David Shu Cheong 許樹昌 |
| 2016.096 | A Phase IIIB, non-randomized, open-label, multi-country, multi-centric cross-vaccination study to evaluate the safety of GSK Biologicals' Herpes Zoster subunit (HZ/su) vaccine when administered intramuscularly on a two-dose schedule to subjects who previously received placebo in ZOSTER-006 and ZOSTER-022 studies. |
Prof. HUI David Shu Cheong 許樹昌 |
| 2014.319 | An observer-blind study to evaluate the safety and immunogenicity of GSK Biologicals’ influenza vaccine(s) GSK3277510A and GSK3277509A administered in adults 18 to 60 years of age. | Prof. HUI David Shu Cheong |
| 2014.640 | A randomised, double-blind, active-controlled parallel group study to evaluate the effect of 52 weeks of once daily treatment of orally inhaled tiotropium + olodaterol fixed dose combination compared with tiotropium on Chronic Obstructive Pulmonary Disease (COPD) exacerbation in patients with severe to very severe COPD. | Prof. HUI David Shu Cheong |
| 2017.238 | A prospective, epidemiological, multi-country, cohort study to assess the occurrence of potential bacterial and viral pathogens in stable chronic obstructive pulmonary disease (COPD) and during acute exacerbations of COPD (AECOPD), in moderate to very severe COPD patients, in Asia Pacific. |
Prof. HUI David Shu Cheong 許樹昌 |
| 2014.334 | Randomized, double-blind, placebo-controlled, multicenter study comparing Ciprofloxacin DPI 32.5 mg BID intermittently administered for 28 days on / 28 days off or 14 days on / 14 days off versus placebo to evaluate the time to first pulmonary exacerbation and frequency of exacerbations in subjects with non-cystic fibrosis bronchiectasis | Prof. HUI David Shu Cheong |
| 2014.417 | A phase III, 52 week, randomized, double-blind, 3-arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF/UMEC/VI with the fixed dose dual combinations of FF/VI and UMEC/VI, all administered once-daily in the morning via a dry powder inhaler in subjects with chronic obstructive pulmonary disease | Prof. HUI David Shu Cheong |
| 2021.298 | Prevalence of non-alcoholic fatty liver disease among non-obese obstructive sleep apnea by using transient elastography | Prof. HUI David Shu Cheong |
| 2023.628 | Long-term longitudinal comparisons of health status and immune responses in elderly cohorts with seasonal influenza vaccine in Hong Kong | Prof. HUI David Shu Cheong |
| 2022.407 | A phase 3b, open-label, multi-country, multi-centre, long-term follow-up study of ZOSTER-049 (follow- up of ZOSTER-006/022 studies) to assess the prophylactic efficacy, safety and persistence of immune response of a Herpes Zoster subunit vaccine and assessment of persistence of immune response and safety of 1 or 2 additional doses administered in ZOSTER-049 in 2 subgroups of older adults. | Prof. HUI David Shu Cheong |
| 2021.032 | A PHASE III OPEN LABEL EXTENSION STUDY TO EVALUATE LONG TERM SAFETY AND EFFICACY OF PRM 151 IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF) |
Prof. HUI David Shu Cheong 許樹昌教授 |
| 2022.412 | Study on Clinical Use of EVUSHELD (AZD7442) in the Real-world Setting – A Multicentre, Single-arm, Observational Study to Determine the Utilisation and Clinical Outcomes of EVUSHELD in China |
Prof. HUI David Shu Cheong 許樹昌教授 |
| 2022.646 | Early Prednisolone for Suspected Community-acquired Acute Respiratory Tract Infection (PREDICATE): A Double-blind, Randomised, Multi-centre, Adaptive Platform, Controlled Trial | Prof. HUI David Shu Cheong |
| 2011.312 | Ethnic and Gender Comparison of Craniofacial Phenotypes in Obstructive Sleep Apnoea | Prof Hui David SC Hui |
| 2011.005 | Validation of the new COPD Assessment Test (CAT) translated into Chinese in patients with Chronic Obstructuve Pulmonary Disease (COPD) | Prof Hui David SC Hui |
| 2014.345 | Obstructive sleep apnoea and CPAP treatment response in patients with non-alcoholic fatty liver disease | Prof. HUI David S.C. |
| 2009.451 | A Pilot Phase 2, Open-Label, Randomized Study of the Antiviral Activity, Safety, and Tolerability of Intravenous Peramivir in Adult Hospitalized Subjects with Confirmed Pandemic H1N1 Influenza Infection | Prof Hui David |
| 2019.067 | The influence of emotion regulation on physiological changes in couple conflict discussion |
Dr. HUI Chin Ming 許展明 |
| 2020.012 | Spousal coordination across transition to parenthood: Its associations with physical and psychological well-being |
Dr. HUI Chin Ming 許展明 |
| 2019.066 | Spousal coordination across transition to parenthood: Its prenatal antecedents and links with health and relationship well-being |
Dr. HUI Chin Ming 許展明 |
| 2019.550 | CATALYST 207: A PHASE 2, PILOT, EXPLORATORY STUDY EVALUATING THE SAFETY AND ANTIVIRAL EFFICACY OF INARIGIVIR SOPROXIL IN NON-CIRRHOTIC TREATMENT-NAÏVE SUBJECTS INFECTED WITH CHRONIC HEPATITIS B VIRUS |
Dr. HUI Aric Josun 許祖紳醫生 |
| 2020.340 | Response after End of Treatment with Antivirals in Chronic Hepatitis B |
Dr. HUI Aric Josun 許祖紳 |
| 2014.590 | CENTAUR: Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Subjects with Liver Fibrosis | Dr. HUI Aric Josun |
| 2015.290 | Direct Discharge of Patients with Upper gastrointestinal bleeding from the Emergency Department after Endoscopy: A Feasibility Study |
Dr. HUI Aric Josun 許祖紳 |
| 2017.164 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis |
Dr. HUI Aric Josun 許祖紳 |
| 2017.531 | A Phase 2, Open-label Study to Evaluate the Safety and Efficacy of Switching to Tenofovir Alafenamide (TAF) from Tenofovir Disoproxil Fumarate (TDF) and/or Other Oral Antiviral Treatment (OAV) in Virologically Suppressed Chronic Hepatitis B Subjects with Renal and/or Hepatic Impairment |
Dr. HUI Aric Josun 許祖紳醫生 |
| 2017.165 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH) |
Dr. HUI Aric Josun 許祖紳 |
| 2015.585 | The Hong Kong HCV Registry |
Dr. HUI Aric Josun 許祖紳 |
| 2014.591 | A Phase IIB-III, open-label, randomized, comparative study to assess the efficacy of ABX203 to maintain control of Hepatitis B disease after cessation of treatment with nucleos(t)ide analogs in adult HBeAg negative patients with chronic Hepatitis B in the Asia Pacific region | Dr. HUI Aric Josun |
| 2014.610 | A Risk Score derived from a large Gastrointestinal Bleeding Registry with Retrospective Validation | Dr. HUI Aric Josun |
| 2011.527 | Safety & Effectiveness of Nurse Performed Colonoscopies under Supervision: A Randomized Controlled Study in Asia (NE Study) | DR HUI ARIC JOSUN |
| 2011.180 | A randomized, double-blind, placebo-controlled trial of the efficacy and safety of DEB025/Alisporivir in combination with peg-IFN | Dr Hui Aric Josun |
| 2010.530 | A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study of FG-3019 in Subjects with Liver Fibrosis due to Chronic Hepatitis B Infection | Dr. HUI Aric Josun |
| 2011.225 | A Phase 4, Randomized, Open-label, Active-Controlled, Superiority Study to Evaluate the Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) in Combination with Peginterferon α-2a (Pegasys®) versus Standard of Care Tenofovir Disoproxil Fumarate Monotherapy or Peginterferon α-2a Monotherapy for 48 Weeks in Non-Cirrhotic Subjects with HBeAg-Positive or HBeAg-Negative Chronic Hepatitis B (CHB) | Dr. Hui Aric Josun |
| 2013.117 | An Open Label, Phase 2a, Single-Arm Study of the Antifibrotic Activity of FG-3019 in Subjects with Advanced Liver Fibrosis due to Chronic Hepatitis C Infection (HCV) | Dr. Hui Aric Josun |
| 2012.550 | A multicenter open-label study to evaluate the safety and efficacy of PEG-Intron™ versus PEGASYS™ in subjects with HBeAg positive chronic hepatitis B and HBeAg negative chronic hepatitis B | Dr. HUI Aric Josun |
| 2009.354 | A pharmacokinetic/pharmacodynamic evaluation of ABF656 in subjects with chronic hepatitis B, eAg+, infection | Dr Hui Aric Josun |
| 2012.101 | A Structured Nurse-led Clinic after Open Access Endoscopy for Patients with Functional Dyspepsia: A Randomized Controlled Study | Dr. HUI Aric Josun |
| 2012.539 | An open-label trial of 48-week peginterferon alfa-2a (PGEASYS) to assess the sustained response of chroinc hepatitis B patients with HBeAg seroconversion on nucleot(s)ide analogue therapy | Dr. HUI Aric Josun |
Page 161 of 265.